Pages that link to "Q73521968"

The following pages link to Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity (Q73521968):

Displaying 21 items.

• Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control (Q30311891) (← links)
• A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside (Q33724878) (← links)
• Targeting MARCO can lead to enhanced dendritic cell motility and anti-melanoma activity (Q33819701) (← links)
• A Randomized Trial ofEx vivoCD40L Activation of a Dendritic Cell Vaccine in Colorectal Cancer Patients: Tumor-Specific Immune Responses Are Associated with Improved Survival (Q34365990) (← links)
• Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine (Q34677842) (← links)
• Silencing of the TGF-β1 Gene Increases the Immunogenicity of Cells From Human Ovarian Carcinoma (Q35890860) (← links)
• Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12 (Q36761540) (← links)
• Dendritic cell-Ewing's sarcoma cell hybrids enhance antitumor immunity (Q36803613) (← links)
• A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. (Q36958112) (← links)
• Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. (Q37154132) (← links)
• Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients (Q37178648) (← links)
• Drug or vaccine?: selecting the appropriate treatment for malignant glioma patients (Q37778052) (← links)
• Chemokines: can effector cells be redirected to the site of the tumor? (Q37778693) (← links)
• Therapeutic vaccines in renal cell carcinoma (Q37922585) (← links)
• Immunotherapy for the Treatment of Glioblastoma (Q37980026) (← links)
• Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells (Q39079690) (← links)
• Use of dentritic cells pulsed with HLA-A2-restricted MAGE-A1 peptide to generate cytotoxic T lymphocytes against malignant glioma (Q39633756) (← links)
• The immunotherapeutic effect of dendritic cells vaccine modified with interleukin-18 gene and tumor cell lysate on mice with pancreatic carcinoma (Q41894628) (← links)
• Dendritic cells based immunotherapy (Q43043935) (← links)
• Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells (Q73342991) (← links)
• A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer (Q84965626) (← links)